Showing 5411-5420 of 6036 results for "".
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated
- Ribomic Enters License Agreement with AJU Pharma for RBM-007 in AMDhttps://modernod.com/news/ribomic-enters-license-agreement-with-aju-pharma-for-rbm-007-in-amd/2477400/Ribomic announced that it has signed a license agreement with Korean pharmaceutical company AJU Pharm Co. for RBM-007 for the indication of the exudative age-related macular degeneration (AMD) in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Mala
- The Outpatient Ophthalmic Surgery Society (OOSS) Releases Statement Regarding COVID-19 Outbreakhttps://modernod.com/news/ooss-releases-statement-regarding-covid-19-outbreak/2477392/The Outpatient Ophthalmic Surgery Society (OOSS) has released a statement to its membership providing information and resources on how to establish ASC procedures if your community is directly affected by the COVID-19 outbreak. The statement reads: Dear Colleagues, In the cu
- ARVO Annual Meeting Cancelledhttps://modernod.com/news/arvo-annual-meeting-cancelled/2477380/Due to the COVID-19 outbreak, the Board of Trustees at The Association for Research in Vision and Ophthalmology (ARVO) has decided to cancel its annual meeting, scheduled to take place May 1–7 in Baltimore. The ARVO organizers released an emailed statement to its membership outlining the d
- Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Diseasehttps://modernod.com/news/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular-disease/2477378/Aldeyra Therapeutics announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M
- Nicox Updates on Zerviate Progress in China and Expands the Countries of its Agreement with Ocumension Therapeuticshttps://modernod.com/news/nicox-updates-on-zerviate-progress-in-china-and-expands-the-countries-of-its-agreement-with-ocumension-therapeutics/2477370/Nicox SA announced that it has amended its March 2019 license agreement with Ocumension Therapeutics granting Ocumension exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in
- AAD Annual Meeting Becomes Latest Casualty of COVID-19 Outbreakhttps://modernod.com/news/aad-annual-meeting-becomes-latest-casualty-of-covid-19-outbreak/2477371/The American Academy of Dermatology (AAD) annual meeting became the latest casualty of the COVID-19 outbreak, with the conference cancelled on Tuesday. The meeting was scheduled to be held from March 20 to 24
- Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucomahttps://modernod.com/news/sight-sciences-announces-publication-of-first-ever-multicenter-migs-study-in-childhood-glaucoma/2477366/Sight Sciences announced that positive outcomes from a new multicenter study of one of the OMNI Surgical System’s predecessor devices, TRAB360, were published in the
- Analysts Give Gilead’s Remdesivir 50% Chance of Success as COVID-19 Treatmenthttps://modernod.com/news/analysts-give-gileads-remdesivir-50-chance-of-success-as-covid-19-treatment/2477362/Analysts at RBC Capital Markets suggested that it is a toss-up whether Gilead Sciences’ remdesivir will succeed in demonstrating efficacy and ultimately securing approval to treat COVID-19, citing limited dosing results, confounding data and previous disappointments in Ebola. “[The] b
- Jim Mazzo Receives the Ellis Island Medal of Honorhttps://modernod.com/news/jim-mazzo-receives-the-ellis-island-medal-of-honor/2477358/Jim Mazzo, Global President of Ophthalmic Devices with Carl Zeiss Meditec, has been chosen to receive the Ellis Island Medal of Honor in 2020. The Ellis Island Honors Society honors the importance of immigration to America’s prosperity and celebrates the contributions immigrants and their